Literature DB >> 14655831

Citalopram in anorexia nervosa.

S Pallanti1, L Quercioli, A Ramacciotti.   

Abstract

Thirthy-two female patients who had been diagnosed as having anorexia nervosa restricting subtype according to the DSM IV (Diagnostic and Statistical Manual of Mental Disorders-IV), were enrolled in a 6-month open trial with citalopram at a starting dose of 20 mg. At the end of the trial, 46.9% of the patients showed a satisfactory response, 34.4% an unsatisfactory response, improvement criteria being weight improvement, menstruation and score reduction on the Symptoms Checklist 90R. Anorectics also showed significant improvement in several Eating Disorder Inventory-2 (EDI-2) scores at the end of the trial, with greater improvement related to satisfactory response to citalopram. Data suggest that SSRI (Selective Serotonin Reuptake Inhibitor) Citalopram could be effective at least in a subgroup of anorectic patients, both on clinically objective and on subjective aspects of anorexia nervosa.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 14655831     DOI: 10.1007/bf03339979

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  25 in total

1.  Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.

Authors:  P M Haffmans; L Timmerman; C A Hoogduin
Journal:  Int Clin Psychopharmacol       Date:  1996-09       Impact factor: 1.659

2.  A structured behaviorally oriented group treatment for bulimia nervosa.

Authors:  R G Laessle; S Waadt; K M Pirke
Journal:  Psychother Psychosom       Date:  1987       Impact factor: 17.659

3.  A comparison of the antidepressant action of citalopram and amitriptyline.

Authors:  D M Shaw; D R Thomas; M H Briscoe; S E Watkins; R Crimmins; B Harris; J Lovett; M Raj; A T Lloyd; C Osborne
Journal:  Br J Psychiatry       Date:  1986-10       Impact factor: 9.319

4.  Letter: Amitriptyline therapy in anorexia nervosa.

Authors:  I H Mills
Journal:  Lancet       Date:  1976-09-25       Impact factor: 79.321

Review 5.  Eating disorders and depression: is there a serotonin connection?

Authors:  D C Jimerson; M D Lesem; W H Kaye; A P Hegg; T D Brewerton
Journal:  Biol Psychiatry       Date:  1990-09-01       Impact factor: 13.382

6.  Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study.

Authors:  J Biederman; D B Herzog; T M Rivinus; G P Harper; R A Ferber; J F Rosenbaum; J S Harmatz; R Tondorf; P J Orsulak; J J Schildkraut
Journal:  J Clin Psychopharmacol       Date:  1985-02       Impact factor: 3.153

Review 7.  Serotonin activity in anorexia and bulimia nervosa: relationship to the modulation of feeding and mood.

Authors:  W H Kaye; T E Weltzin
Journal:  J Clin Psychiatry       Date:  1991-12       Impact factor: 4.384

8.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

9.  Anorexia nervosa: directions for future research. Study Group on Anorexia Nervosa.

Authors: 
Journal:  Int J Eat Disord       Date:  1995-04       Impact factor: 4.861

10.  Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group.

Authors:  D J Goldstein; M G Wilson; V L Thompson; J H Potvin; A H Rampey
Journal:  Br J Psychiatry       Date:  1995-05       Impact factor: 9.319

View more
  2 in total

1.  A setting including psychotherapy and psychopharmacological treatment in a case of anorexia nervosa with obsessive compulsive disorder comorbidity.

Authors:  A Ramacciotti; S Pallanti; A Pazzagli
Journal:  Eat Weight Disord       Date:  1997-12       Impact factor: 4.652

Review 2.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.